Browse drugs

…likely to be coded with S09.90 (aOR=0.79, 95% CI 0.68 to 0.91). S09.90 use was also associated with female patients and absence of com…

…nitis (n=2), myasthenia gravis (n=1), and sicca syndrome (n=1). JAKi were employed as second-line therapy in 7 patients, third-line …

…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…

…(–2.6 vs –1.5; p=0.0172).Conclusion These findings suggest that fremanezumab provides an effective preventive migraine treatment option in c…

…ATTR amyloidosis therapy during this period), all patients with Val122Ile hATTR were referred, leading to an unselected cohort.Results We…

… or moderate-efficacy DMTs, an emulated a target trial compared DMT escalation within 6 months of a silent lesion versus unchanged …

…o], ocular [3.5/nipocalimab; 2.8/placebo], and respiratory [1.1/nipocalimab; 1.0/placebo]. Mean CFB favored nipocalimab (p<0.05), with resp…

…t an average dose of 11.6mg/day. Compared to patients on a peak prednisolone dose of ≤40mg, patients with a peak dose >40mg were more likely…

…tments in 2021EAN/PNS guidelines. SCIg is better tolerated than IVIg, increases patient compliance, autonomy, quality of life and ca…

…ent with national prescribing guidance (to switch patients onto edoxaban).Intervention Complex intervention including a SMOR embedded wi…

…at least once prescribed reimbursed medication—glucocorticoids (prednisolone or methylprednisolone), conventional synthetic disease-modifyin…

…talisations. This trial will bridge the gap for the efficacy of budesonide/formoterol in children <12 years of age and address the economic arguments…